The AI Factor: Why Cash Still Flows To European Biotech Startups

Putting the Tech In Bio: Why Cash Still Flows To European Biotech Startups

Amid ongoing concerns about declining VC funding in the United Kingdom, Biotech startups have been doing rather well. According to the U.K. Bio Association, businesses working in the sector raised £563 million in venture capital and public funding in the three months to September. Following a sluggish start to the year, the Association predicts the industry is on course to exceed the levels of funding seen in 2022. Meanwhile, KPMG’s latest U.K. Venture Pulse report notes that Biotech – along with AI and climate tech – is set to dominate the investment agenda.

Related News

How I Closed a $1 Million Domain Deal Without Risking Losing the Domain or the Money

First-Time Business Buyers Are Changing How Deals Get Done — Here’s What Sellers Need to Know

Man allegedly killed girlfriend in Berkeley, stuffed her body in a suitcase

Market sell-off accelerates as traders raise odds for Fed rate hikes

NASA declares MAVEN, its Mars atmosphere orbiter, dead

Xavier Becerra advances to November runoff of CA governor’s race, NBC News projects